Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 29Multiple Myeloma 16Neoplasms 9Recurrence 8Lymphoma 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Carcinoma, Ovarian Epithelial 7Lymphoma, Non-Hodgkin 6Sarcoma 5Neoplasm Metastasis 5Burkitt Lymphoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Leiomyosarcoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × liposomal doxorubicin × Clear all
NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡